GIM2试验:激素受体阳性/HER2阴性早期乳腺癌免疫组化Luminal亚型对剂量密集辅助化疗疗效的探索性分析
该探索性分析基于GIM2试验中淋巴结阳性早期乳腺癌患者,按Ki67和PgR免疫组化定义Luminal A样与B样亚型,比较剂量密集(DD)与标准间隔化疗的疗效。结果显示治疗与亚型间无显著交互作用(DFS交互P=0.603,OS交互P=0.535),但Luminal B样队列似乎从DD方案中获益更多(DFS未校正HR 0.72,95%CI 0.54-0.96;OS未校正HR 0.61,95%CI 0.40-0.94)。
要点
- Luminal B样(Ki67≥20%和/或PgR<20%)患者接受DD化疗DFS和OS获益更明显。
- Luminal A样(Ki67<20%且PgR≥20%)患者DD化疗的未校正HR未显示显著获益。
- 治疗与Luminal亚型间交互作用不显著,亚组获益需谨慎解读。
核心结论
- Luminal样亚型与治疗方案间无显著交互作用,但Luminal B样队列似乎从剂量密集方案中获益更多。
研究设计与样本
- GIM2试验的探索性分析,纳入2003例淋巴结阳性早期乳腺癌患者,其中Luminal A样412例、Luminal B样638例。
- 患者随机接受剂量密集或标准间隔蒽环类序贯紫杉醇辅助化疗。
- Luminal A样定义为Ki67<20%且PgR≥20%,Luminal B样定义为Ki67≥20%和/或PgR<20%。
主要发现
- 中位随访7.9年,Luminal A样与B样队列的DFS分别为80.8%(95%CI 76.4-84.5)和70.5%(66.5-74.2)。
- Luminal A样与B样队列的OS分别为91.6%(88.2-94.1)和85.1%(81.7-87.9)。
- 治疗与亚型交互作用P值:DFS为0.603,OS为0.535。
- Luminal B样队列DD vs 标准间隔:DFS未校正HR 0.72(95%CI 0.54-0.96),OS未校正HR 0.61(95%CI 0.40-0.94)。
- Luminal A样队列DD vs 标准间隔:DFS未校正HR 0.89(95%CI 0.59-1.33),OS未校正HR 0.83(95%CI 0.45-1.54)。
临床怎么用
- 对激素受体阳性/HER2阴性、淋巴结阳性的早期乳腺癌,Luminal B样免疫组化表型患者可优先考虑剂量密集辅助化疗。
- Luminal A样患者采用剂量密集方案需个体化权衡,因该亚组未显示显著获益且交互作用不显著。
局限性
- 为探索性分析,亚组样本量有限,结果需前瞻性验证。
- Luminal亚型采用免疫组化定义,非基因表达分型。
- 亚组HR为未校正分析,交互作用不显著,亚组结论应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. METHODS: Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) ≥ 20%; luminal B-like cohort as having a Ki67 ≥ 20% and/or a PgR < 20%. RESULTS: Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). CONCLUSIONS: No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule.
引用
- Conte B, Bruzzone M, Lambertini M, et al. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. Eur J Cancer. 2020. PMID: 32634760. doi:10.1016/j.ejca.2020.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。